Kura Oncology Inc (KURA) concluded trading on Wednesday at a closing price of $9.12, with 3.98 million shares of worth about $36.28 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.12% during that period and on December 18, 2024 the price saw a loss of about -6.37%. Currently the company’s common shares owned by public are about 77.75M shares, out of which, 65.25M shares are available for trading.
Stock saw a price change of -10.59% in past 5 days and over the past one month there was a price change of -43.14%. Year-to-date (YTD), KURA shares are showing a performance of -36.58% which decreased to -26.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.40 but also hit the highest price of $24.17 during that period. The average intraday trading volume for Kura Oncology Inc shares is 1.35 million. The stock is currently trading -14.99% below its 20-day simple moving average (SMA20), while that difference is down -38.40% for SMA50 and it goes to -52.18% lower than SMA200.
Kura Oncology Inc (NASDAQ: KURA) currently have 77.75M outstanding shares and institutions hold larger chunk of about 97.52% of that.
The stock has a current market capitalization of $709.21M and its 3Y-monthly beta is at 0.77. It has posted earnings per share of -$2.36 in the same period. It has Quick Ratio of 11.47 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KURA, volatility over the week remained 5.74% while standing at 6.44% over the month.
Stock’s fiscal year EPS is expected to drop by -14.67% while it is estimated to increase by 13.38% in next year. EPS is likely to grow at an annualized rate of 19.93% for next 5-years, compared to annual growth of -3.94% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $27 to it. Coverage by Stifel stated Kura Oncology Inc (KURA) stock as a Hold in their note to investors on October 14, 2024, suggesting a price target of $19 for the stock. On December 22, 2023, Mizuho Initiated their recommendations, while on August 11, 2023, BofA Securities Initiated their ratings for the stock with a price target of $31. Stock get a Sector perform rating from Scotiabank on July 27, 2023.
